Correspondence 0001213900-24-055007 from Neuphoria Therapeutics Inc. (NEUP) (CIK 0001191070) (NEUP)
Neuphoria Therapeutics Inc. (NEUP) (CIK 0001191070)
Date: June 24, 2024 · CIK: 0001191070 · Accession: 0001213900-24-055007
AI Filing Summary & Sentiment
File numbers found in text: 333-280288
Letter
via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Chris Edwards Registration Statement on Form F-1 Filed June 18, 2024 Securities Act File No. 333-280288 Request for Acceleration of Effectiveness
Dear Mr. Edwards:
Pursuant to Rule 461 of Regulation C under the Securities Act of 1933, as amended, Bionomics Limited (the “Registrant”) respectfully requests acceleration of its Registration Statement on Form F-1 (File No. 333-280288), filed on June 18, 2024, so that it will become effective at 9:00 a.m. (Eastern time) on June 26, 2024, or as soon as practicable thereafter.
If you have any questions, or require any additional information, please do not hesitate to email Theodore Ghorra, the Registrant’s outside counsel, at theodore.ghorra@rimonlaw.com or by phone at 212-515-9979.
The Registrant acknowledges that, if the Securities and Exchange Commission (or its staff, acting pursuant to delegated authority) (the “Commission”) declares the filing effective, such action:
(i) does not foreclose the Commission from taking any action with respect to the filing;
(ii) does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
(iii) may not be asserted by the Registrant as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Bionomics Limited
Show Raw Text
CORRESP
1
filename1.htm
Bionomics Limited
200 Greenhill Road
Eastwood, SA 5063
Australia
June 24, 2024
via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention: Chris Edwards
Re:
Bionomics Limited
Registration Statement on Form F-1
Filed June 18, 2024
Securities Act File No. 333-280288
Request for Acceleration of Effectiveness
Dear Mr. Edwards:
Pursuant to Rule 461 of Regulation C under
the Securities Act of 1933, as amended, Bionomics Limited (the “Registrant”) respectfully requests acceleration of its Registration
Statement on Form F-1 (File No. 333-280288), filed on June 18, 2024, so that it will become effective at
9:00 a.m. (Eastern time) on June 26, 2024, or as soon as practicable thereafter.
If you have any questions, or require any
additional information, please do not hesitate to email Theodore Ghorra, the Registrant’s outside counsel, at theodore.ghorra@rimonlaw.com
or by phone at 212-515-9979.
The Registrant acknowledges that, if the Securities
and Exchange Commission (or its staff, acting pursuant to delegated authority) (the “Commission”) declares the filing effective,
such action:
(i) does
not foreclose the Commission from taking any action with respect to the filing;
(ii) does
not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
(iii) may
not be asserted by the Registrant as a defense in any proceeding initiated by the Commission or any person under the federal securities
laws of the United States.
Very truly yours,
Bionomics Limited
By:
/s/ Spyridon Papapetropoulos
Spyridon Papapetropoulos, M.D.
Chief Executive Officer
cc:
Theodore J. Ghorra, Esq., Rimon P.C.
Andrew Reilly, Esq., Rimon P.C.